Source link : https://www.newshealth.biz/health-news/pi3k-inhibitor-wins-fda-approval-for-advanced-breast-cancer/
The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and fulvestrant to treat locally advanced, PIK3CA-mutated, hormone receptor (HR)-positive/HER2-negative breast cancer that recurred during or after adjuvant endocrine therapy. Support for the approval came from the multicenter randomized INAVO120 trial, which showed that the addition of inavolisib to palbociclib […]
Author : News Health
Publish date : 2024-10-10 21:34:44
Copyright for syndicated content belongs to the linked Source.